CVS Group plc (CVSGF) Shareholder/Analyst Call Transcript

Core Insights - CVS Group reported continued progress in providing care to animals during the interim results for the six-month period ending December 2025 [2] - The company completed its transition from AIM to the main market on January 29, 2026, aiming for improved liquidity and access to a diverse pool of capital [2] Company Developments - A new consumer-facing U.K. companion animal joint brand under CVS Vets has been launched, reflecting the company's commitment to care, value, and service [3] - CVS Group's presence in Australia is expanding, with three acquisitions completed in the reporting period and two additional practice acquisitions in the second half of the year [3] - The company has maintained disciplined capital investment to enhance facilities, clinical equipment, and technology, which is expected to drive long-term growth in shareholder value [3] Industry Engagement - CVS Group welcomes the launch of a consultation by DEFRA regarding the Veterinary Surgeons Act from 1966 and is actively engaging in the process [4] - The company is anticipating the final decision from the CMA in the coming weeks [4]